



## Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lsyc20>

### Novel Four-Step Synthesis of Thioxo-quinazolino[3,4-a]quinazolinone Derivatives

Behnaz Shafii<sup>a</sup>, Mina Saeedi<sup>a</sup>, Mohammad Mahdavi<sup>a</sup>, Alireza Foroumadi<sup>a</sup> & Abbas Shafiee<sup>a</sup>

<sup>a</sup> Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

Accepted author version posted online: 27 Aug 2013. Published online: 29 Oct 2013.

To cite this article: Behnaz Shafii, Mina Saeedi, Mohammad Mahdavi, Alireza Foroumadi & Abbas Shafiee (2014) Novel Four-Step Synthesis of Thioxo-quinazolino[3,4-a]quinazolinone Derivatives, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 44:2, 215-221, DOI: [10.1080/00397911.2013.800211](https://doi.org/10.1080/00397911.2013.800211)

To link to this article: <http://dx.doi.org/10.1080/00397911.2013.800211>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing,


systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

## NOVEL FOUR-STEP SYNTHESIS OF THIOXO-QUINAZOLINO[3,4-*a*]QUINAZOLINONE DERIVATIVES

Behnaz Shafii, Mina Saeedi, Mohammad Mahdavi,  
 Alireza Foroumadi, and Abbas Shafiee

Department of Medicinal Chemistry, Faculty of Pharmacy and  
 Pharmaceutical Sciences Research Center, Tehran University of  
 Medical Sciences, Tehran, Iran

### GRAPHICAL ABSTRACT



**Abstract** A novel synthesis of thioxo-quinazolino[3,4-*a*]quinazolinone framework was developed through a four-step reaction starting from isatoic anhydride. The resulting 2-aminobenzamides from the reaction of isatoic anhydride and different amines underwent coupling–cyclization reaction with 2-nitrobenzaldehydes, reduction of nitro group, and then cyclization reaction with carbon disulfide ( $\text{CS}_2$ ). All steps were carried out under easy and user-friendly conditions in a short time without using expensive catalysts or reagents.

[Supplementary materials are available for this article. Go to the publisher's online edition of Synthetic Communications<sup>®</sup> for the following free supplemental resource(s): Full experimental and spectral details.]


**Keywords** Carbon disulfide ( $\text{CS}_2$ ); heterocycles; 2-nitrobenzaldehydes; thioxo-quinazolino[3,4-*a*]quinazolinone

## INTRODUCTION

The prominence of the quinazoline unit in various medicinal organic compounds has been the subject of great interest because of its medicinal and distinguished biological activities.<sup>[1]</sup> The quinazolinone and quinazolinthione

Received March 5, 2013.

Address correspondence to Abbas Shafiee, Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14176, Iran. E-mail: ashafiee@ams.ac.ir




**Figure 1.** Structure of isolated 2-(4-hydroxybenzyl)quinazolin-4(3*H*)-one **A** and farinamycin **B** from *Cordyceps*-colonizing fungus *Isaria farinosa* and *Streptomyces griseus*, respectively.

(thioxo-quinazolinone) moieties are well known for their anticonvulsant,<sup>[2]</sup> antihypertensive,<sup>[3]</sup> anti-inflammatory,<sup>[4]</sup> and phosphodiesterase inhibitor<sup>[5]</sup> properties. Recently, Corbett et al. showed that fused quinazolines were HIV-1 non-nucleoside reverse transcriptase inhibitors.<sup>[6]</sup> More to the point, the quinazolinone nucleus can be found in natural products such as 2-(4-hydroxybenzyl)quinazolin-4(3*H*)-one (Fig. 1, **A**) obtained from cultures of the *Cordyceps*-colonizing fungus *Isaria farinosa*<sup>[7]</sup> and farinamycin (Figure 1, **B**), a quinazoline metabolite isolated from *Streptomyces griseus*.<sup>[8]</sup>

Unfortunately, the biological and medical activities of the quinazolinethiones have not been fully investigated yet. Recently, Bahekar et al. investigated quinazolinethione derivatives and found that they showed bronchodilator activity using in vitro and in vivo methods (standard animal models).<sup>[9]</sup> In addition, El Azab et al. described the synthesis of novel quinazolinone and quinazolinethione derivatives that showed potential as antitumor agents.<sup>[10]</sup> A literature review revealed that quinazolinethione has been center of attention not only for the biological properties but also they have been suitable intermediates for the preparation of useful bioactive compounds.<sup>[11]</sup>

As part of our ongoing research program pertaining to the synthesis and design of new heterocyclic compounds,<sup>[12–14]</sup> we have devised a novel synthetic scheme to obtain fused thioxo-quinazolino[3,4-*a*]quinazolinones, and we realized that their synthesis and biological activities were not fully understood. Thus, we tried to present a suitable protocol for the synthesis of this class of heterocycles and thioxo-quinazolino[3,4-*a*]quinazolinone derivatives (Scheme 1).



**Scheme 1.** Synthesis of fused thioxo-quinazolino[3,4-*a*]quinazolinones **6**: (i) in water at room temperature (2–3 h); (ii) 2-nitrobenzaldehyde or 3-methoxy-2-nitrobenzaldehyde,  $K_2CO_3$ /EtOH at reflux (2–4 h); (iii) Zn,  $NH_4Cl$ , MeOH, water at room temperature (1–2 h); (iv)  $CS_2$  (excess), KOH/EtOH at reflux (3–5 h).

## RESULTS AND DISCUSSION

We recently reported synthesis of diverse new heterocyclic compounds starting from isatoic anhydride.<sup>[12,15]</sup> Because of the good results and easy procedure, we were encouraged to design a novel strategy for the synthesis of quinazolino[3,4-*a*]quinazolinones utilizing isatoic anhydride. For this purpose, we outlined a synthetic route in four steps for the preparation of these compounds (Scheme 1).

The first step of our synthetic route included preparation of various 2-amino-benzamide derivatives **3** from the reaction of isatoic anhydride **1** and various amines **2** in water at room temperature.<sup>[12,15]</sup> Clearly the reaction is conducted by the nucleophilic attack of amine on the isatoic anhydride with liberation of CO<sub>2</sub>.<sup>[16]</sup>

The second step of our synthetic scheme was preparing the 2,3-dihydro-2-(2-nitrophenyl)-3-arylquinazolin-4(1*H*)-one derivatives **4**. A literature survey shows that there are various procedures for the one-pot, three-component synthesis of quinazolin-4(1*H*)-ones starting from isatoic anhydride, amines, and aldehydes.<sup>[17]</sup> We investigated some of these procedures and obtained the related products **4** in poor yields. It seems that those methods did not work as efficiently as we expected for the selected sterically hindered aldehydes in our study. Also some of them used complex or expensive catalysts.<sup>[18]</sup> We observed that heating mixture of a stoichiometric amount of 2-aminobenzamides **3**, 2-nitrobenzaldehyde derivatives, and potassium carbonate (K<sub>2</sub>CO<sub>3</sub>) in EtOH led to the formation of compounds **4** in good yields.


In the third step, reduction of nitro group in compounds **4** gave 2-(2-aminophenyl)-2,3-dihydro-3-arylquinazolin-4(1*H*)-ones **5**. It should be noted that the best reaction conditions for reduction of the NO<sub>2</sub> group was obtained using a mixture of Zn powder and ammonium chloride (NH<sub>4</sub>Cl) in MeOH/H<sub>2</sub>O, at room temperature.

In the fourth step, the final products **6** were obtained easily by heating the mixture of compounds **5** and an excess amount of carbon disulfide (CS<sub>2</sub>) in the presence of potassium hydroxide (KOH).

The structure of all products was confirmed on the basis of their mass spectroscopic fragmentation pattern analysis and <sup>1</sup>H and <sup>13</sup>C NMR spectra. For instance, for 12-benzyl-6-thioxo-11b,12-dihydro-6*H*-quinazolino[3,4-*a*]quinazolin-13(7*H*)-one **6a** (Table 1, entry 1), the MS peak (*m/z* 371) associated with the molecular ion was observed and was in accordance with calculated mass for C<sub>22</sub>H<sub>17</sub>N<sub>3</sub>OS. The MS shows a strong peak (*m/z* 237) that is related to elimination of the benzyl and CS groups and the formation of 2-(2-aminophenyl)quinazolin-4(1*H*)-one. Also a rather strong peak was also observed (*m/z* 266) resulting from the loss of phenylmethanimine.

<sup>1</sup>H NMR spectrum of **6a** consisted of two doublet signals at 4.06 and 4.81 for the two protons of NCH<sub>2</sub> and a singlet at 6.67 ppm for CH. The 13 protons associated with the aromatic rings were observed around 6.71–8.01 ppm. The singlet signal at 11.61 corresponded to the NH group. As expected, the <sup>13</sup>C spectrum exhibited 20 distinct resonances. Two signals at 44.0 and 68.6 are related to two aliphatic carbons. Sixteen signals related to aromatic carbons were observed around 113.0–142.5. Two signals at 162.9 and 175.4 ppm are related to C=O and C=S, respectively.

As can be seen in Table 1, we could synthesize various thioxo-quinazolino[3,4-*a*]quinazolinone derivatives through the described method. It is worth mentioning that all 2-aminobenzamides showed good reactivity toward 2-nitrobenzaldehydes

**Table 1.** Synthesis of fused thioxo-quinazolino[3,4-*a*]quinazolinone derivatives **6**

Entry	R	X	Product <b>6</b>	Yield (%) <sup>a</sup>
1	C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub> -	H	<b>6a</b>	88
2	C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub> -	OMe	<b>6b</b>	80
3	4-Me-C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> -	H	<b>6c</b>	82
4	4-Me-C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> -	OMe	<b>6d</b>	79
5	4-F-C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> -	H	<b>6e</b>	80
6	4-F-C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> -	OMe	<b>6f</b>	80
7	2-Cl-C <sub>6</sub> H <sub>4</sub> CH <sub>2</sub> -	H	<b>6g</b>	81
8	Furfuryl	H	<b>6h</b>	75
9	CH <sub>2</sub> =CHCH <sub>2</sub> -	H	<b>6i</b>	84
10	CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub> -	H	<b>6j</b>	81

<sup>a</sup>Isolated yields.

and all of corresponding products tolerated reduction reaction and also cyclization reaction with CS<sub>2</sub>. It should be noted that different electron-donating and electron-withdrawing substituents on either *para* or *ortho* positions of aromatic rings did not show remarkable differences in the yield of products and reaction times. In the case of products **6h**, lower yield can be related to electron-withdrawing effect of furfuryl, which decreased the nucleophilicity of NH<sub>2</sub> group of furfurylamine and also NH in 2-amino-*N*-((furan-2-yl)methyl)benzamide.

## CONCLUSION

In summary, we have developed a novel and efficient four-step synthesis of fused thioxo-quinazolino[3,4-*a*]quinazolinone derivatives starting from isatoic anhydride as an available starting material, in moderate to good yields. All four steps included easy and user friendly procedures which did not diminish yields of products significantly. All steps were done without using expensive catalyst and reagents in short time. Noticing that synthesis and biological evaluation of the title compounds have not been investigated, we hope that the described strategy for the synthesis of these potentially bioactive products can open a new horizon for organic and medicinal chemists. These compounds may possess cytotoxic activities.

## EXPERIMENTAL

Melting points were taken on a Kofler hot-stage apparatus and are uncorrected. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker FT-500, using tetramethylsilane (TMS) as an internal standard. The infrared (IR) spectra were obtained on a Nicolet Magna FTIR 550 spectrophotometer (KBr disks). Mass spectra were recorded on an

Agilent Technology (HP) mass spectrometer operating at an ionization potential of 70 eV. Elemental analyses were carried out with a Perkin-Elmer model 240-C apparatus.

### Synthesis of Thioxo-Quinazolino[3,4-*a*]quinazolinone Derivatives 6: General Procedure

A mixture of 2-(2-aminophenyl)-2,3-dihydro-3-arylquinazolin-4(1*H*)-one derivatives **5** (2 mmol), carbon disulfide (CS<sub>2</sub>) (5 mmol), and potassium hydroxide (KOH) (2 mmol) in EtOH (10 mL) was heated at reflux for 3–5 h. After completion of the reaction (checked by thin-layer chromatography, TLC), the reaction mixture was cooled down to room temperature and poured into ice-cold water, and the white precipitates were filtered off and recrystallized from EtOH to give pure products **6**.

### 12-(4-Fluorobenzyl)-8-methoxy-6-thioxo-11b,12-dihydro-6*H*- quinazolino[3,4-*a*]quinazolin-13(7*H*)-one (**6f**)

Yield: 0.33 g (80%); white crystal; mp 220–222 °C. IR (KBr): 3440, 3152, 3118, 3026, 1648, 1602, 1517, 1430, 1180 cm<sup>-1</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ = 3.80 (s, 3 H, OMe), 4.02 (d, *J* = 15.9 Hz, 1 H, benzylic), 4.84 (d, *J* = 15.9 Hz, 1 H, benzylic), 6.65 (s, 1 H, CH), 6.70–6.73 (m, 2 H, H<sub>9</sub>, H<sub>10</sub>), 6.92–6.96 (m, 3 H, H<sub>11</sub>, H<sub>3'</sub>, H<sub>5'</sub>), 7.09–7.16 (m, 2 H, H<sub>2'</sub>, H<sub>6'</sub>), 7.51 (t, *J* = 8.0 Hz, 1 H, H<sub>2</sub>), 7.63 (dt, *J* = 8.0, 1.1 Hz, 1 H), 7.68 (d, *J* = 8.0 Hz, 1 H, H<sub>4</sub>), 8.00 (dd, *J* = 8.0, 1.1 Hz, 1 H, H<sub>1</sub>), 10.00 (s, 1 H, NH). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ = 43.4, 56.2, 68.6, 113.1, 114.1, 114.6 (d, *J*<sub>C-F</sub> = 21.2 Hz), 120.5, 124.1, 124.3, 126.0, 127.1, 127.3, 127.5, 127.9 (d, *J*<sub>C-F</sub> = 7.8 Hz), 130.9, 133.8, 142.6, 144.9, 160.9 (d, *J*<sub>C-F</sub> = 240.7 Hz), 162.9, 175.6. MS: *m/z* (%) = 419 (35) [M]<sup>+</sup>, 296 (100), 267 (49), 253 (40), 237 (31), 162 (23), 134 (12), 109 (66), 77 (18). Anal. calcd. for C<sub>23</sub>H<sub>18</sub>FN<sub>3</sub>O<sub>2</sub>S: C, 65.86; H, 4.33; N, 10.02. Found: C, 65.59; H, 4.55; N, 9.86.

## SUPPORTING INFORMATION

Full experimental details and <sup>1</sup>H and <sup>13</sup>C NMR spectra are available. This material can be found via the Supplementary Content section of this article's Web page.

## ACKNOWLEDGMENTS

This research was supported by grants from the research council of Tehran University of Medical Sciences, Iran National Science Foundation (INSF), and Iran National Elite Foundation (INEF).

## REFERENCES

1. (a) Dhimi, K. S.; Arona, S. S.; Narang, K. S. Thiopegan derivatives, XXIII: Synthesis of 5*H*-thiazolo[3,2-*a*]quinazolin-5-one and 5*H*-thiazolo[2,3-*b*]quinazolin-5-one derivatives containing phenolic, alkoxy, and alkyl groups. *J. Med. Chem.* **1963**, *6*, 450–452; (b) Bonola, G.; Re, P. D.; Magistretti, M. J.; Massarani, E.; Setnikar, I. 1-Aminoacyl-2,3-dihydro-4(1*H*)-quinazolinone derivatives with choleretic and antifibrillatory activity.

- J. Med. Chem.* **1968**, *11*, 1136–1139; (c) Bavetsias, V.; Skelton, L. A.; Yafai, F.; Mitchell, F.; Wilson, S. C.; Allan, B.; Jackman, A. L. The design and synthesis of water-soluble analogues of CB30865, a quinazolin-4-one-based antitumor agent. *J. Med. Chem.* **2002**, *45*, 3692–3702.
2. (a) Wenzel, D. G. Anticonvulsant activity of some uracils and related compounds. *J. Am. Pharm. Assoc.* **1955**, *44*, 550–553; (b) Hori, M.; Iemura, R.; Hara, H.; Ozaki, A.; Sukamoto, T.; Ohtaka, H. Novel 4-phenoxy-2-(1-piperazinyl)quinazolines as potent anticonvulsive and antihypoxic agents. *Chem. Pharm. Bull.* **1990**, *38*, 681–687.
  3. (a) Hayao, S.; Havera, H. J.; Stryker, W. G.; Leipzig, T. J.; Kulp, R. A.; Hartzler, H. E. New sedative and hypotensive 3-substituted 2,4(1*H*,3*H*)-quinazolinoidiones. *J. Med. Chem.* **1965**, *8*, 807–811; (b) Havera, H. J. Derivatives of 1,3-disubstituted 2,4(1*H*,3*H*)-quinazolinoidiones as possible peripheral vasodilators or antihypertensive agents. *J. Med. Chem.* **1979**, *22*, 1548–1550.
  4. Chao, Q.; Deng, L.; Shih, H.; Leoni, L. M.; Genini, D.; Carson, D. A.; Cottam, H. B. Substituted isoquinolines and quinazolines as potential anti-inflammatory agents: Synthesis and biological evaluation of inhibitors of tumor necrosis factor  $\alpha$ . *J. Med. Chem.* **1999**, *42*, 3860–3873.
  5. Witt, A.; Bergman, J. Recent developments in the field of quinazoline chemistry. *Curr. Org. Chem.* **2003**, *7*, 659–677.
  6. Corbett, J. W.; Pan, S.; Markwalder, J. A.; Cordova, B. C.; Klabe, R. M.; Garber, S.; Rodgers, J. D.; Erickson-Viitanen, S. K. 3,3a-Dihydropyrano[4,3,2-*de*]quinazolin-2(1*H*)-ones are potent non-nucleoside reverse transcriptase inhibitors. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 211–214.
  7. Ma, C.; Li, Y.; Niu, S.; Zhang, H.; Liu, X.; Che, Y. N-Hydroxypyridones, phenylhydrazones, and a quinazolinone from *Isaria farinose*. *J. Nat. Prod.* **2011**, *74*, 32–37.
  8. Nett, M.; Hertweck, C. Farinamycin, a quinazoline from *Streptomyces griseus*. *J. Nat. Prod.* **2011**, *74*, 2265–2268.
  9. Bahekar, R. H.; Rao, R. R. Synthesis, evaluation, and structure–activity relationships of 5-alkyl-2,3-dihydroimidazo[1,2-*c*]quinazoline, 2,3-dihydroimidazo[1,2-*c*]quinazolin-5(6*H*)-thiones, and their oxo-analogues as new potential bronchodilators. *Arzneim Forsch Drug Res.* **2001**, *51*, 284–292.
  10. El-Azab, A. S.; Al-Omar, M. A.; Abdel-Aziz, A. A.-M.; Abdel-Aziz, N. I.; El-Sayed, M. A.-A.; Aleisa, A. M.; Sayed-Ahmed, M. M.; Abdel-Hamide, S. G. Design, synthesis, and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. *Eur. J. Med. Chem.* **2010**, *45*, 4188–4198.
  11. Decker, M. Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine. *Eur. J. Med. Chem.* **2005**, *40*, 305–313.
  12. Mahdavi, M.; Asadi, M.; Saeedi, M.; Rezaei, Z.; Moghbel, H.; Foroumadi, A.; Shafiee, A. Synthesis of novel 1,4-benzodiazepine-3,5-dione derivatives: Reaction of 2-amino-benzamides under Bargellini reaction conditions. *Synlett.* **2012**, *23*, 2521–2525.
  13. Mahdavi, M.; Asadi, M.; Saeedi, M.; Ebrahimi, M.; Rasouli, M. A.; Ranjbar, P. R.; Foroumadi, A.; Shafiee, A. One-pot, four-component synthesis of novel imidazo[2,1-*b*]thiazol-5-amine derivatives. *Synthesis* **2012**, *44*, 3649–3654.
  14. Azizmohammadi, M.; Khoobi, M.; Ramazani, A.; Emami, S.; Zarrin, A.; Firuzi, O.; Miri, R.; Shafiee, A. 2*H*-Chromene derivatives bearing thiazolidine-2,4-dione, rhodanine, or hydantoin moieties as potential anticancer agents. *Eur. J. Med. Chem.* **2013**, *59*, 15–22.
  15. (a) Mahdavi, M.; Asadi, M.; Saeedi, M.; Tehrani, M. H.; Mirfazli, S. S.; Shafiee, A.; Foroumadi, A. Green synthesis of new boron-containing quinazolinones: Preparation of benzo[d][1,3,2]diazaborinin-4(1*H*)-one derivatives. *Synth. Commun.* **2013**, *43*, 2936–2942; (b) Asadi, M.; Ebrahimi, M.; Mahdavi, M.; Saeedi, M.; Ranjbar, P. R.; Yazdani, F.; Shafiee, A.; Foroumadi, A. Reaction of isatoic anhydride, amines and *N,N'*-dialkylcarbodiimides



- under solvent-free conditions: New and efficient synthesis of 3-alkyl-2-(alkylamino)quinazolin-4(3*H*)-ones. *Synth. Commun.* **2013**, *43*, 2385–2392.
16. Clark, R. H.; Wagner, E. C. Isatoic anhydride, I: Reactions with primary and secondary amines and with some amides. *J. Org. Chem.* **1944**, *9*, 55–67.
17. (a) Wang, S.; Yin, S.; Xia, S.; Shi, Y.; Tu, S.; Rong, L. An efficient synthesis of 3-benzylquinazolin-4(1*H*)-one derivatives under catalyst-free and solvent-free conditions. *Green Chem. Lett. Rev.* **2012**, *5*, 603–607; (b) Karimi-Jaberi, Z.; Arjmandi, R. Acetic acid-promoted, efficient, one-pot synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones. *Monatsh. Chem.* **2011**, *142*, 631–635; (c) Chen, J.; Wu, D.; He, F.; Liu, M.; Wu, H.; Ding, J.; Su, W. Gallium(III) triflate-catalyzed one-pot selective synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones and quinazolin-4(3*H*)-ones. *Tetrahedron Lett.* **2008**, *49*, 3814–3818.
18. (a) Wang, L.-M.; Hu, L.; Shao, J.-H.; Yu, J.; Zhang, L. A novel catalyst zinc(II) perfluorooctanoate [Zn(PFO)<sub>2</sub>]-catalyzed three-component one-pot reaction: Synthesis of quinazolinone derivatives in aqueous micellar media. *J. Fluorine Chem.* **2008**, *129*, 1139–1145; (b) Saffar-Teluri, A.; Bolouk, S. One-pot, three-component synthesis of 2,3-dihydroquinazolin-4(1*H*)-ones using *p*-toluenesulfonic acid–paraformaldehyde copolymer as an efficient and reusable catalyst. *Monatsh. Chem.* **2010**, *141*, 1113–1115.